title: [Neuroprotector effect of human recombinant erythropoietin sorbed on polymer nanoparticles studied on model of intracerebral post-traumatic hematoma (hemorrhagic stroke)].
abstract: The neuroprotective activity of recombinant human erythropoietin (r-HuEpo) sorbed on poly(butyl)cyanoacrilate nanoparticles (EPO-PBCA) and on polylactic-co-glycolic acid nanoparticles (EPO-PLGA) has been studied on Wistar rats with intracerebral post-traumatic hematoma (model of hemorrhagic stroke) (IPH-HS) in comparison to native r-HuEpo. It is established that EPO-PBCA produced a protective effect in rats after IPH-HS that was manifested by a decrease in the number of animals with neurological disorders such as circus movement, paresis, and paralysis of hind limbs; the drug also improved coordination (rotating rod test), reduced the number of lost animals, and decreased the loss weight among survived rats. In addition, EPO-PBCA optimized the research behavior of rats with IPH-HS in the open field test and prevented amnesia of passive avoidance reflex (PAR), which was caused by the IPH-HS. These effects were manifested during a two-week observation period. EPO-PLGA has a similar but much less pronounced effect on the major disorders caused by IPH-HS. The efficiency of native r-HuEpo as a neuropotective agent was insignificant and only manifested by decrease in the number of lost animals with IPH-HS.
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Balaban'ian
authors.forename: I N
authors.initials: IN
authors.lastname: Solev
authors.forename: O S
authors.initials: OS
authors.lastname: Elizarova
authors.forename: T L
authors.initials: TL
authors.lastname: Garibova
authors.forename: S A
authors.initials: SA
authors.lastname: Litvinova
authors.forename: T A
authors.initials: TA
authors.lastname: Voronina
mesh_terms: D000327:Adsorption; D000647:Amnesia / Q000188:drug therapy / Q000517:prevention & control; D000818:Animals; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000523:psychology; D004195:Disease Models, Animal; D004659:Enbucrilate / Q000737:chemistry; D004921:Erythropoietin / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D053758:Nanoparticles / Q000737:chemistry*; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D010243:Paralysis / Q000188:drug therapy / Q000517:prevention & control; D010291:Paresis / Q000188:drug therapy / Q000517:prevention & control; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000523:psychology; D015996:Survival Rate; D015431:Weight Loss / Q000187:drug effects
chemical_list: D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004659:Enbucrilate